Big Drug, Small Panel: US FDA Adcomm For Eisai/Biogen’s Leqembi Includes Only Six Voting Members
Leqembi's clinical benefit and safety will be evaluated by just a half dozen voting experts at a 9 June advisory committee meeting. • Source: Shutterstock
